80 related articles for article (PubMed ID: 7505087)
1. The ligands of the class II major histocompatibility complex-restricted T cells.
Demotz S
Chem Immunol; 1993; 57():18-38. PubMed ID: 7505087
[No Abstract] [Full Text] [Related]
2. Cognate MHC-TCR interaction leads to apoptosis of antigen-presenting cells.
Setterblad N; Blancheteau V; Delaguillaumie A; Michel F; Bécart S; Lombardi G; Acuto O; Charron D; Mooney N
J Leukoc Biol; 2004 Jun; 75(6):1036-44. PubMed ID: 14982950
[TBL] [Abstract][Full Text] [Related]
3. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
[TBL] [Abstract][Full Text] [Related]
4. Costimulation and endogenous MHC ligands contribute to T cell recognition.
Wülfing C; Sumen C; Sjaastad MD; Wu LC; Dustin ML; Davis MM
Nat Immunol; 2002 Jan; 3(1):42-7. PubMed ID: 11731799
[TBL] [Abstract][Full Text] [Related]
5. Induction of thymocyte deletion by purified single peptide/major histocompatibility complex ligands.
Lesage S; Charron J; Winslow G; Hugo P
J Immunol; 1997 Sep; 159(5):2078-81. PubMed ID: 9278291
[TBL] [Abstract][Full Text] [Related]
6. Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat.
Sayegh MH; Khoury SJ; Hancock WW; Weiner HL; Carpenter CB
Transplant Proc; 1993 Feb; 25(1 Pt 1):357-8. PubMed ID: 8438333
[No Abstract] [Full Text] [Related]
7. From fragments to immunity.
Nat Immunol; 2004 Jul; 5(7):659. PubMed ID: 15224090
[No Abstract] [Full Text] [Related]
8. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
9. Unique T cell antagonist properties of the exact self-correlate of a peptide antigen revealed by self-substitution of non-self-positions in the peptide sequence.
Schountz T; Kasselman JP; Ford SR; Murray JS
Cell Immunol; 1996 Mar; 168(2):193-200. PubMed ID: 8640865
[TBL] [Abstract][Full Text] [Related]
10. Lack of fair play in the T cell response.
Lanzavecchia A
Nat Immunol; 2002 Jan; 3(1):9-10. PubMed ID: 11753400
[No Abstract] [Full Text] [Related]
11. Alloantigen processing and presentation.
Tambur AR; Gebel HM
J Heart Lung Transplant; 1995; 14(6 Pt 1):1031-7. PubMed ID: 8719446
[No Abstract] [Full Text] [Related]
12. Alloantigen presentation by B cells: analysis of the requirement for B-cell activation.
Wilson JL; Cunningham AC; Kirby JA
Immunology; 1995 Nov; 86(3):325-30. PubMed ID: 8550066
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides.
Francis MJ
Methods Mol Med; 2003; 87():115-32. PubMed ID: 12958453
[No Abstract] [Full Text] [Related]
15. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
16. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of generation and persistence on membrane class II molecules of a viral peptide expressed on foreign and self proteins.
Bot A; Bot S; Antohi S; Karjalainen K; Bona C
J Immunol; 1996 Oct; 157(8):3436-42. PubMed ID: 8871642
[TBL] [Abstract][Full Text] [Related]
18. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
19. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
20. Constitutive presentation of dominant epitopes from endogenous naturally processed self-beta 2-microglobulin to class II-restricted T cells leads to self-tolerance.
Guéry JC; Sette A; Appella E; Adorini L
J Immunol; 1995 Jan; 154(2):545-54. PubMed ID: 7814867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
